USFDA issues response letter for new drug application for insulin glargine: Biocon

Biocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news